Correction to: Cancer Cell Int (2021) 21:356 https://doi.org/10.1186/s12935-021-02072-x
In this article [1], the author name “Xiaobin Wu” was incorrectly written as “Xianbin Wu”. This has been corrected in this correction.
In addition, there was a printing mistake in Table 7. The correct information of 1714 is 14, 1417 is 17, 5350 is 50 and 6669 is 69. The corrected Table 7 is given below.
Reference
Wu X, Han R, Zhong Y, Weng N, Zhang A. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Cancer Cell Int. 2021;21:356. https://doi.org/10.1186/s12935-021-02072-x.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Wu, X., Han, R., Zhong, Y. et al. Correction to: Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Cancer Cell Int 21, 693 (2021). https://doi.org/10.1186/s12935-021-02401-0
Accepted:
Published:
DOI: https://doi.org/10.1186/s12935-021-02401-0